Dr. Peter Doshi - Archive

We Tried to Improve COVID Vaccine Labeling — The FDA Said ‘No Thanks’ By Dr. Peter Doshi, Prof. Linda Wastila, and Kim Witczak, June 13, 2023
Serious Adverse Events of Special Interest Following mRNA COVID-19 Vaccination in Randomized Trials in Adults By Joseph Fraiman, Juan Erviti, Dr. Peter Doshi, and et al., September 07, 2022
Does the FDA Think These Data Justify the First Full Approval of a COVID-19 Vaccine? BMJ By Dr. Peter Doshi, September 02, 2021
Why We Petitioned the FDA to Refrain from Fully Approving Any COVID-19 Vaccine this Year By Prof. Linda Wastila, Dr. Peter Doshi, Hamid Merchant, and Kim Witczak, June 09, 2021
In Rush for Regulatory Approval of COVID Vaccines, Do We Need More Data? By Dr. Peter Doshi, May 19, 2021
British Medical Journal: Pfizer and Moderna’s “95% Effective” Vaccines—Let’s be Cautious and First See the Full Data By Dr. Peter Doshi, January 19, 2021
Pfizer and Moderna’s “95% Effective” Vaccines—Let’s be Cautious and First See the Full Data By Dr. Peter Doshi, December 03, 2020
“Influenza: Marketing Vaccine by Marketing Disease.” Report on Flu Vaccines in British Medical Journal By Dr. Peter Doshi, August 22, 2017